Researchers at the University of British Columbia demonstrated the first successful human transplant of a kidney converted from blood type A to universal type O using specialized enzyme technology. The process removes blood group antigens to reduce rejection risks. In a brain-dead donor model, the enzyme-converted kidney functioned without hyperacute rejection for two days; mild reactions emerged by day three but with less damage than typical mismatched transplants. This decade-long effort promises faster, safer transplants and improved organ availability, especially benefiting patients awaiting compatible kidneys.